Barrett's Esophagus and Esophageal Adenocarcinoma

被引:14
|
作者
Bresalier, Robert S. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA
来源
ANNUAL REVIEW OF MEDICINE | 2009年 / 60卷
关键词
esophageal metaplasia; dysplasia; endoscopy; biomarkers; prevention; HIGH-GRADE DYSPLASIA; GASTROESOPHAGEAL-REFLUX DISEASE; BODY-MASS INDEX; ENDOSCOPIC RESECTION; ABDOMINAL OBESITY; INTESTINAL METAPLASIA; EARLY NEOPLASIA; CANCER-RISK; BILE-ACIDS; FOLLOW-UP;
D O I
10.1146/annurev.med.59.061206.112706
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The incidence of esophageal adenocarcinoma (EAC) has risen dramatically over the past three decades in western countries. The importance of Barrett's esophagus (BE) derives from its potential to transform to adenocarcinoma. BE, is characterized by endoscopically recognized displacement of the squamocolumnar junction proximal to the gastroesophageal junction, with replacement of squamous mucosa with columnar lined mucosa. Adenocarcinomas of the esophagus appear to arise from Barretts mucosa through progressive degrees of dysplasia, but the pathogenesis and natural history of this process are still unclear. Much of our knowledge regarding BE and the risk of EAC is based on observational and cross-sectional analyses, and recommendations regarding management have traditionally represented "expert opinion." The past few years have seen an explosion in new information and the initiation of longitudinal studies to define the risk of adenocarcinoma in BE, the identification of predictive and prognostic markers of cancer risk, sensitive and cost-effective methods of surveillance, and methods of management of dysplasia and early neoplasia including disease prevention.
引用
收藏
页码:221 / 231
页数:11
相关论文
共 50 条
  • [1] Barrett's esophagus and esophageal adenocarcinoma
    Sarisley, Christine
    [J]. GASTROENTEROLOGY NURSING, 2008, 31 (01) : 76 - 77
  • [2] Barrett's Esophagus and esophageal Adenocarcinoma
    Bloemer, M.
    Jaehne, J.
    [J]. CHIRURG, 2013, 84 (03): : 232 - 232
  • [3] Chemoprevention in Barrett's esophagus and esophageal adenocarcinoma
    Alkhayyat, Motasem
    Kumar, Prabhat
    Sanaka, Krishna O.
    Thota, Prashanthi N.
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [4] Focus on Barrett's esophagus and esophageal adenocarcinoma
    Paulson, TG
    Reid, BJ
    [J]. CANCER CELL, 2004, 6 (01) : 11 - 16
  • [5] Advances in Barrett's esophagus and esophageal adenocarcinoma
    Shaheen, NJ
    [J]. GASTROENTEROLOGY, 2005, 128 (06) : 1554 - 1566
  • [6] Familial Barrett’s Esophagus and Esophageal Adenocarcinoma
    Joel Gabre
    Amitabh Chak
    Anil Rustgi
    [J]. Current Treatment Options in Gastroenterology, 2020, 18 (4) : 616 - 622
  • [7] Barrett's Esophagus and Esophageal Adenocarcinoma Biomarkers
    Grady, William M.
    Yu, Ming
    Markowitz, Sanford D.
    Chak, Amitabh
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (12) : 2486 - 2494
  • [8] Biomarkers of esophageal adenocarcinoma and Barrett's esophagus
    McManus, DT
    Olaru, A
    Meltzer, SJ
    [J]. CANCER RESEARCH, 2004, 64 (05) : 1561 - 1569
  • [9] MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma
    Kan, Takatsugu
    Meltzer, Stephen J.
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2009, 9 (06) : 727 - 732
  • [10] Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma
    Runge, Thomas M.
    Abrams, Julian A.
    Shaheen, Nicholas J.
    [J]. GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2015, 44 (02) : 203 - +